October 20, 2025Brazilian Journal of TransplantationOpen Access

Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Kidney Transplant Recipients: Impact on Glycemic Control, Graft Function, and Proteinuria

View Full Paper

Ask AI

Bookmark

Graft function remained stable in diabetic kidney transplant recipients treated with SGLT2 inhibitors over two years.
Among 31 transplant recipients treated, 45.2% had pre-transplant diabetes and 54.8% had post-transplant diabetes.
No significant changes in fasting blood glucose, estimated glomerular filtration rate, or proteinuria were observed in either group.
The treatment was well tolerated, with low rates of adverse events like urinary tract infections.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Observational analysis examines glycemic control and graft function in diabetic kidney transplant recipients treated with SGLT2 inhibitors, suggesting potential benefits.

Cite This Study

Rossi et al. (2025) studied this question.

synapsesocial.com/papers/68f58f68ece7a5b64f4714ac https://doi.org/10.53855/bjt.v28i1.717_eng

View Full Paper

Ask AI

Bookmark

Implication

Observational analysis examines glycemic control and graft function in diabetic kidney transplant recipients treated with SGLT2 inhibitors, suggesting potential benefits.

Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Kidney Transplant Recipients: Impact on Glycemic Control, Graft Function, and Proteinuria

Key Points

Discussion

Implication

Cite This Study

Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Kidney Transplant Recipients: Impact on Glycemic Control, Graft Function, and Proteinuria

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider